General
Preferred name
CINNARIZINE
Synonyms
Stugeron|Dimitronal|Stutgin|Cinarizine ()
Stugeron, Dimitronal, Stutgin, Cinarizine ()
1-(diphenylmethyl)-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine ()
Stutgin ()
Glanil ()
Artate ()
Cinarizine ()
Spaderizine ()
Sepan ()
Mylan Travel Sickness ()
Stunarone ()
516 MD ()
Cinnipirine ()
Labyrin ()
Stutgeron ()
Aplexal ()
Processine ()
Aplactan ()
Hilactan ()
Cerebolan ()
NSC-758400 ()
R 1575 ()
Mitronal ()
Midronal ()
Cinaperazine ()
Katoseran ()
516-MD ()
R 516 ()
Cerepar ()
R-516 ()
Stugeron ()
Olamin ()
Cinarizina ()
Siptazin ()
Stugeron Fte ()
Cinnacet ()
Ixertol ()
Eglen ()
Carecin ()
Corathiem ()
Giganten ()
Sedatromin ()
Folcodal ()
Cinnageron ()
Dimitron ()
R-1575 ()
Marzine R.F. ()
Cinazyn ()
Denapol ()
P&D ID
PD002810
CAS
16699-20-0
298-57-7
Tags
available
drug
Drug indication
Vertigo meniere disease
Vertigo
Drug Status
approved
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Cinnarizine is used primarily for its anti-histaminic activity, but it also has anti-cholinergic and calcium channel blocking effects, which may account for some of its side-effects.The INN record for this drug specifies cinnarizine clofibrate (PubChem CID 6436096). Cinnarizine is the parent molecule of the fluorine derivative . Both of these compounds induce parkinsonism as an adverse effect , likely due to antagonism of D2 receptors by the parent molecules and/or some of their bioactive metabolites . (GtoPdb)
PRICE 29
DESCRIPTION Cinnarizine is an orally active, effective and selective inhibitor of L-type calcium channel Cav1.3 with an IC50 of 1.5 ¦ÌM (in vestibular hair cells). Cinnarizine can cross the blood-brain barrier and regulate calcium homeostasis and dopamine neurotransmission. Cinnarizine inhibits the influx of calcium ions into smooth muscle cells by blocking L-type calcium channels, thereby relaxing vascular smooth muscle, improving cerebral circulation and reducing blood viscosity, while antagonizing dopamine receptors. Cinnarizine can be used in the study of vestibular vertigo, Meniere's disease and cerebrovascular diseases[1][2][3][4][5].
DESCRIPTION Cinnarizine (Stugeron) is a piperazine derivative having histamine H1-receptor and calcium-channel blocking activity with vasodilating and antiemetic properties but it induces PARKINSONIAN DISORDERS.
DESCRIPTION Ca2+ channel blocker; central and peripheral vasodilator (LOPAC library)
DESCRIPTION Cinnarizine is an antihistamine and a calcium channel blocker. It is used for the management of labyrinthine disorder symptoms, including vertigo, tinnitus, nystagmus, nausea, and vomiting. (Enamine Bioactive Compounds)
DESCRIPTION PUBCHEM_BIOASSAY: qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] (TargetMol Bioactive Compound Library)
Cell lines
4
Organisms
1
Compound Sets
19
Cayman Chemical Bioactives
21001
ChEMBL Drugs
CHEMBL43064
Drug Repurposing Hub
DrugBank
DB00568
DrugBank Approved Drugs
DB00568
DrugCentral
654
DrugCentral Approved Drugs
654
DrugMAP
DM7U5QJ
DrugMAP Approved Drugs
DM7U5QJ
Enamine Bioactive Compounds
EBC-85024
Guide to Pharmacology
9072
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL43064
MedChem Express Bioactive Compound Library
HY-B1090
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
cinnarizine
TargetMol Bioactive Compound Library
R033-0071
External IDs
36
Properties
(calculated by RDKit )
Molecular Weight
368.23
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
0
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
3
cLogP
5.11
TPSA
6.48
Fraction CSP3
0.23
Chiral centers
0.0
Largest ring
6.0
QED
0.6
Structural alerts
2
aggregator (Aggregator Advisor)
Aggregators
aggregator (ZINC)
Aggregators
Related compounds
Custom attributes
(extracted from source data)
Indication
Meniere's disease, nausea, vomiting, Cogan's syndrome
Disease Area
neurology/psychiatry, gastroenterology, ophthalmology
MOA
calcium channel blocker
Target
Calcium Channel
Histamine Receptor
Therapeutic Class
Antiallergic Agents
Pathway
GPCR/G protein
Immunology/Inflammation
Membrane Transporter/Ion Channel
Neuronal Signaling
Source data